Allergan, Inc. (AGN), HCA Holdings Inc (HCA), Gilead Sciences, Inc. (GILD) Among Healthcare Stocks That Billionaires Love

Page 1 of 2

The healthcare sector is one that has been performing very well in the short, but also medium and long-term. Over the last 52 weeks, healthcare stocks returned on average 24.53%, being outrun only by the real estate sector, which appreciated by roughly 25%. In this way, investors that have bet on healthcare stocks managed to collect significant profits from both consolidation of the sector caused by mergers & acquisitions and from some new developments and discoveries in the portfolios of healthcare companies.

Our data for the fourth quarter of 2014, shows that funds that we track have bet on more than 250 healthcare companies, while among the most popular stocks have been large-cap companies or companies that have been acquisition targets. Billionaires also did not stay clear from healthcare companies during the fourth quarter, and disclosed long positions in over 60 companies in the latest round of 13F filings. Among the most popular stocks on which billionaires have been most bullish on is Allergan, Inc. (NYSE:AGN), as well as the company that is currently pursuing its acquisition: Actavis plc (NYSE:ACT). Moreover billionaires also bet on pharmaceutical retailer Walgreens Boots Alliance Inc (NASDAQ:WBA), hospital operator HCA Holdings Inc (NYSE:HCA) and on biotech stocks, with Gilead Sciences, Inc. (NASDAQ:GILDalso making the top five list.

Best Paying Jobs For Women

Allergan, Inc. (NYSE:AGN) and Actavis plc (NYSE:ACT) are the most popular healthcare stocks among investors. Aside from being two of the most popular stocks among billionaires, both companies have also been the most popular healthcare stocks among hedge funds. At the end of the fourth quarter, 19 billionaire investors reported holding shares of Allergan, Inc. (NYSE:AGN) and 18 billionaire-managed funds held shares of Actavis. Earlier in November, Allergan entered into a deal to be acquired by Actavis for $66 billion. The deal managed to overturn the plans of famous activist investor Bill Ackman, who also tried to acquire Allergan together with Valeant Pharmaceuticals for approximately $60 billion. Nevertheless, the talks about the potential acquisition of Allergan, Inc. (NYSE:AGN) sent the stock rallying throughout the second half of 2014 and led to a significant increase in the popularity of the stock among investors. On the other hand, Actavis plc (NYSE:ACT), being one of the top healthcare companies, has always been one of the favorite stocks of equity investors.

Even though Bill Ackman did not succeed in acquiring Allergan, Inc. (NYSE:AGN), the deal with Actavis plc (NYSE:ACT) made the billionaire manager of Pershing Square one of the biggest winners, since his fund held around 26.64 million shares of Allergan. In addition to him, billionaire Daniel S. Och of OZ Management owns shares of both Allergan and Actavis, which represent the two largest stakes in his fund’s equity portfolio as of the end of 2014. Billionaires Larry Robbins, Dan Loeb, and George Soros also decided to take advantage of the merger and initiated new stakes in Allergan during the fourth quarter of 2014. In addition all three billionaires have raised their exposure to Actavis plc (NYSE:ACT) during the October-December period, among others.

Next on the list is hospital and heathcare facilities operator HCA Holdings Inc (NYSE:HCA) in which 15 billionaires disclosed long equity positions, including Larry Robbins and Stephen Mandel, who held 6.18 million shares and 5.84 million shares respectively, Mandel initiating a stake during the fourth quarter. On the other hand, among the over 700 funds that we track, HCA Holdings Inc (NYSE:HCA) has seen a decrease in popularity, with 80 funds reporting long positions, versus 90 funds in the previous quarter. HCA Holdings Inc (NYSE:HCA)’s stock gained around 40% during the last year, on the back of a strong financial performance. Analysts are also optimistic about the company’s prospects, as a couple of days ago, Oppenheimer and Credit Suisse set price targets of $84 and $81 respectively, both with ‘Buy’ ratings. In addition, at last year’s “Alpha Delivering Conference” Larry Robbins said that HCA Holdings is one of the stocks that he likes because the company is able to buy debt at low interest and use the proceeds to engage in activities that provide more value to shareholders such as dividends and buybacks.

Page 1 of 2